Literature DB >> 27718019

Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies.

Masachika Hayashi1, Toshiaki Kikuchi1, Toshinori Takada2,3.   

Abstract

Entities:  

Keywords:  Anti-melanoma differentiation-associated gene 5 antibody; Dermatomyositis; Interstitial lung disease; Mycophenolate mofetil

Mesh：

Substances：

Year:  2016        PMID： 27718019     DOI： 10.1007/s10067-016-3443-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  5 in total

1.  Mycophenolate mofetil for interstitial lung disease in dermatomyositis.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Victoria P Werth
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-10       Impact factor: 4.794

Review 2.  Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.

Authors:  Bornstein Gil; Lidar Merav; Langevitz Pnina; Grossman Chagai
Journal:  Clin Rheumatol       Date:  2015-04-07       Impact factor: 2.980

Review 3.  Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.

Authors:  Zhiyong Chen; Mengshu Cao; Maria Nieves Plana; Jun Liang; Hourong Cai; Masataka Kuwana; Lingyun Sun
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-08       Impact factor: 4.794

4.  Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.

Authors:  Jeffrey J Swigris; Amy L Olson; Aryeh Fischer; David A Lynch; Gregory P Cosgrove; Stephen K Frankel; Richard T Meehan; Kevin K Brown
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

5.  Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.

Authors:  Aryeh Fischer; Kevin K Brown; Roland M Du Bois; Stephen K Frankel; Gregory P Cosgrove; Evans R Fernandez-Perez; Tristan J Huie; Mahalakshmi Krishnamoorthy; Richard T Meehan; Amy L Olson; Joshua J Solomon; Jeffrey J Swigris
Journal:  J Rheumatol       Date:  2013-03-01       Impact factor: 4.666
  5 in total
  7 in total

Review 1.  Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.

Authors:  Roberta Vilela Lopes Koyama; Tiago Kiyoshi Kitabayashi Braga; George Alberto da Silva Dias; Satomi Fujihara; Hellen Thais Fuzii; Gilberto Toshimitsu Yoshikawa
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

Review 2.  Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology.

Authors:  Emily K Wu; Robert D Ambrosini; R Matthew Kottmann; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi
Journal:  Curr Rheumatol Rev       Date:  2019

Review 3.  Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.

Authors:  Robert W Hallowell; Julie J Paik
Journal:  Clin Exp Rheumatol       Date:  2021-03-25       Impact factor: 4.473

4.  Cytokine profiles of amyopathic dermatomyositis with interstitial lung diseases treated with mycophenolate.

Authors:  Masachika Hayashi; Ami Aoki; Katsuaki Asakawa; Takuro Sakagami; Toshiaki Kikuchi; Toshinori Takada
Journal:  Respirol Case Rep       Date:  2017-04-11

Review 5.  Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review.

Authors:  Giulia Cassone; Marco Sebastiani; Caterina Vacchi; Gian Luca Erre; Carlo Salvarani; Andreina Manfredi
Journal:  Drugs Context       Date:  2021-01-15

6.  MDA-5 dermatomyositis complicated by interstitial lung disease and cutaneous ulcers: successful treatment with corticosteroids, mycophenolate mofetil and intravenous immunoglobulin.

Authors:  Kelli Stager; Leanna Wise
Journal:  BMJ Case Rep       Date:  2020-09-30

7.  Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.

Authors:  Yushiro Endo; Tomohiro Koga; Takahisa Suzuki; Kazusato Hara; Midori Ishida; Yuya Fujita; Sosuke Tsuji; Ayuko Takatani; Toshimasa Shimizu; Remi Sumiyoshi; Takashi Igawa; Masataka Umeda; Shoichi Fukui; Ayako Nishino; Shin-Ya Kawashiri; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Masataka Kuwana; Atsushi Kawakami
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.